HalbwertszeitStudienlage & Dosis

Top-Studien zu Halbwertszeit

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

1. 01

   Strategies to improve plasma half life time of peptide and protein drugs.

   Amino acids·2006122 einflussreiche Zitationen

   Due to the obvious advantages of long-acting peptide and protein drugs, strategies to prolong plasma half life time of such compounds are highly on demand. Short plasma half life times are commonly due to fast renal clearance as well as to…

2. 02

   Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.

   Diabetes/metabolism research and reviews·201059 einflussreiche Zitationen

   <h4>Background</h4>Glucagon-like peptide-1 (GLP-1) receptor agonists are novel agents for type 2 diabetes treatment, offering glucose-dependent insulinotropic effects, reduced glucagonemia and a neutral bodyweight or weight-reducing…

3. 03

   Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications.

   International journal of molecular sciences·202538 einflussreiche Zitationen

   Cathelicidins are a family of antimicrobial peptides (AMPs) with broad-spectrum activity and immunomodulatory functions. Among them, the only human cathelicidin LL-37 has garnered significant interest due to its potent antimicrobial,…

4. 04

   Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end.

   Communications biology·202531 einflussreiche Zitationen

   Albumin has a long plasma half-life due to engagement of the neonatal Fc receptor (FcRn), which prevents intracellular degradation. However, its C-terminal end can be cleaved by carboxypeptidase A, and removal of the last leucine residue…

5. 05

   Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.

   Journal of medicinal chemistry·202528 einflussreiche Zitationen

   The past few years have seen the approval of several medications for weight management, but there is an increasing need for new therapies that target different pathways of energy balance. Owing to its role as a physiological satiety signal…

6. 06

   Absorption, distribution, metabolism, and excretion of an antiviral drug-Fc conjugate CD388 following subcutaneous administration of 14 C-CD388 in the rat.

   Drug metabolism and disposition: the biological fate of chemicals·20252 einflussreiche Zitationen

   CD388 is a novel drug-Fc conjugate designed to function as a long-acting antiviral drug by inhibiting proliferation of the influenza virus. This action results from a dimeric form of zanamivir, a neuraminidase inhibitor, conjugated to an…

7. 07

   Preclinical Safety of APG777, A Novel Extended Half-Life Anti-Interleukin-13 Monoclonal Antibody, in Cynomolgus Monkeys.

   International journal of toxicology·20252 einflussreiche Zitationen

   Interleukin-13 (IL-13) is a cytokine implicated in the pathophysiology of type 2 inflammatory diseases and is a clinically validated target in atopic dermatitis. APG777 is a humanized IgG1 monoclonal antibody with an optimized…

8. 08

   Half-life extension of therapeutics: Applications and mechanisms.

   The Journal of pharmacology and experimental therapeutics·20252 einflussreiche Zitationen

   The clinical effectiveness of peptide and protein therapeutics is often limited by their short circulating half-life, necessitating frequent injections. Therefore, half-life extension strategies have emerged as centerpieces in…

9. 09

   First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin-S Inhibitor, in Healthy Adult Subjects.

   Clinical and translational science·20261 einflussreiche Zitationen

   ASP1617 is a novel, highly selective inhibitor of cathepsin-S, an important protease for antigen peptide loading onto major histocompatibility complex class II molecules. Preclinically, ASP1617 prevented progression of lupus-like…

10. 10

    Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potential.

    Cytokine·20251 einflussreiche Zitationen

    Recombinant interleukin-18 (IL-18) holds promise as a therapeutic for oncology, as a robust activator of adaptive and innate immune cells and a potent producer of IFN-γ. However, clinical success has been limited due to rapid upregulation…